Golden Age Health (GAH) is a bi‑directional pharmaceutical platform that links advanced rare‑disease therapies with patients in China and brings high‑potential Chinese biotech assets to global markets. It offers end‑to‑end commercialization—including regulatory dossiers, supply‑chain logistics, AI‑driven patient identification, and value‑based market access—leveraging specialized Chinese pathways such as the Hainan Medical Pilot Zone and Beijing Rare Disease Tianzhu Zone.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with rare and specialty diseases in China often lack timely access to advanced therapies, while promising Chinese biotech assets struggle to reach global markets due to regulatory, commercial, and logistical barriers.
Solution
Golden Age Health (GAH) operates as a bi‑directional pharmaceutical platform that connects cutting‑edge rare‑disease treatments with Chinese patients and sources high‑potential Chinese biotech assets for international development. The company manages the full commercialization value chain—from regulatory dossier preparation and supply‑chain logistics to AI‑driven patient identification, omnichannel engagement, and value‑based market access—ensuring efficient launch and sustained uptake. GAH leverages its deep expertise in China’s unique regulatory pathways, such as the Hainan Medical Pilot Zone and Beijing Rare Disease Tianzhu Zone, to accelerate patient access. Simultaneously, its on‑the‑ground presence identifies and partners with Chinese innovators, structuring flexible deals to bring their products to global markets.
Target Audience
Primary customers are pharmaceutical companies and biotech innovators seeking to launch rare‑disease or specialty therapies in China, as well as Chinese biotech firms looking to commercialize their assets globally.
Features
- End‑to‑end commercialization services covering dossier creation, regulatory filing, manufacturing, and distribution
- AI‑powered real‑world data analytics for precise patient targeting, market sizing, and value‑based access strategies
- Proven playbook for navigating China’s specialty‑drug ecosystem, including fast‑track zones and reimbursement pathways
- Flexible partnership structures that enable co‑development, licensing, and joint‑venture arrangements with Chinese biotech firms
- Integrated supply‑chain management ensuring reliable product availability across diverse geographic regions
- Dedicated market‑access expertise to secure reimbursement and pricing agreements in both China and international markets